Omnicell Earnings Call: Growth Intact, Margins Under Strain

Omnicell ((OMCL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Omnicell Balances Growth Momentum with Margin Strain in Latest Earnings Call

Omnicell’s latest earnings call carried a tone of cautious optimism, as management highlighted solid revenue and recurring revenue growth, strong service trends, and early traction from new platform launches. At the same time, the company acknowledged meaningful pressure on margins, earnings per share, and cash levels driven by tariffs, strategic investments, and a softer bookings backdrop. Management framed these headwinds as temporary and tied to deliberate investments in new products and infrastructure aimed at strengthening Omnicell’s recurring revenue base and positioning the company for multi‑year growth. Execution on cost mitigation, product transition to Titan XT and Omnisphere, and margin recovery emerged as crucial themes for investors.

ARR Growth Underpins Omnicell’s Long-Term Story

Omnicell exited 2025 with annual recurring revenue (ARR) of $636 million, up 10% from the prior year’s exit rate, reinforcing its strategic pivot toward subscription and services. Management guided year-end 2026 ARR to a range of $680 million to $700 million, implying projected growth of roughly 7% to 10% versus the 2025 exit. This steady ARR expansion is central to the investment case, as it signals a growing base of predictable revenue and underlines the company’s progress in shifting away from more volatile, one-time hardware sales toward software, services, and platform-based offerings.

Revenue Growth Shows Steady but Unspectacular Progress

Total revenue for 2025 reached $1.185 billion, up from $1.112 billion in 2024, a year-over-year increase of about 6.6%. Management’s 2026 revenue outlook of $1.215 billion to $1.255 billion points to continued, albeit measured, top-line growth. The mix of product and service revenue remains a key factor, with investors watching not just the growth rate but the quality of that growth—particularly in recurring and higher-margin segments—as Omnicell navigates a more complex cost backdrop.

Bookings and Backlog Provide Visibility, But Momentum Has Softened

Product bookings for 2025 came in at $535 million, landing above the midpoint of guidance but down from $558 million in 2024, a decline of roughly 4.1%. The product backlog ended 2025 at $640 million, down about 1% year over year, with $435 million designated as short-term backlog expected to convert into revenue in 2026. This still gives Omnicell a solid visibility line into the coming year, but the slight pullback in bookings and backlog underscores a more tempered growth environment and the importance of ramping orders for new platforms like Titan XT.

New Platforms Titan XT and Omnisphere Gain Early Traction

Omnicell emphasized momentum in product and platform innovation, led by the launch of Titan XT and the continued buildout of its Omnisphere platform, which achieved a high-trust security certification. Early customer feedback from key industry conferences such as ASHP has reportedly been positive, with notable wins across large health systems, the VA, and Canadian providers. Management highlighted a stronger pipeline and improved top-of-funnel activity, positioning Titan XT and Omnisphere as strategic growth engines that could accelerate adoption and deepen customer relationships over time.

Service Revenue Strengthens Recurring Revenue Base

Service revenue was a clear bright spot. Full-year 2025 service revenue rose to $519 million from $482 million in 2024, a 7.7% increase, while fourth-quarter 2025 service revenue of $134 million grew 8% year over year. This expansion in services further fuels ARR and helps stabilize Omnicell’s earnings profile. The growth demonstrates that once systems are installed, the company continues to monetize those relationships through maintenance, software, and other service offerings, supporting a more defensible business model.

Product Revenue Continues to Grow, Driven by Connected Devices

Product revenue also advanced, though at a moderate pace. For 2025, product revenue climbed to $666 million from $631 million in 2024, an increase of about 5.6%. Management attributed this growth largely to demand for connected devices within the XT family of products. While this underscores continued relevance of Omnicell’s hardware platform, the company is simultaneously pushing toward more software and data-driven solutions, which could carry higher margins over time if adoption of platforms like Titan XT and Omnisphere accelerates.

EBITDA and EPS Guidance Point to Gradual Profit Recovery

Non-GAAP EBITDA for full-year 2025 rose modestly to $140 million from $136 million in 2024, a 2.9% increase, reflecting positive operating leverage but also cost pressures. For 2026, Omnicell is guiding non-GAAP EBITDA to a range of $145 million to $160 million, signaling expected continued expansion, while non-GAAP EPS guidance of $1.65 to $1.85 suggests modest improvement from 2025’s level. Management stressed that profit growth is expected to outpace revenue growth by roughly 2x in 2026, indicating a focus on efficiency and margin recovery despite ongoing investments.

Operational Improvements Boost Working Capital Efficiency

Operational execution showed tangible improvement in receivables management. Days Sales Outstanding (DSO) improved to 65 days in 2025 from 77 days in 2024, pointing to better collections and tighter working capital control. This improvement is particularly important given the company’s concurrent pressure on cash balances, as it frees up internal financing capacity and supports the funding of ongoing strategic initiatives without undue reliance on external capital.

Gross Margin Hit by Tariffs and Mix Shift

A major pressure point was gross margin. Full-year non-GAAP gross margin dropped to 43.2% in 2025 from 47.4% in 2024, a decline of about 4.2 percentage points. Management attributed this largely to roughly $7 million in tariff-related costs and shifts in product and customer mix. Looking ahead to 2026, the company expects tariffs to have an even larger impact, estimating about $15 million in tariff costs hitting the P&L. While mitigation efforts are in progress, the guidance acknowledges these will remain a meaningful headwind in the near term, forcing Omnicell to balance pricing, cost controls, and product mix to protect profitability.

Earnings and EPS Reflect Near-Term Profit Pressure

Earnings metrics highlight the near-term profitability challenges. In the fourth quarter of 2025, GAAP EPS swung to a loss of $0.05, compared with GAAP EPS of $0.34 in the prior-year quarter. On a non-GAAP basis, Q4 EPS declined to $0.40 from $0.60 year over year, while full-year non-GAAP EPS slipped to $1.62 from $1.71, a decline of roughly 5.3%. These figures reflect the combined impact of tariff costs, deliberate investment spending, and mix shifts, setting a lower earnings base from which management aims to rebuild.

Quarterly EBITDA Pressured by Strategic Investments

Quarterly profitability also came under pressure. Q4 2025 non-GAAP EBITDA fell to $37 million from $46 million a year earlier, a decline of about 19.6%, landing at the lower end of management’s guidance range. The company cited higher expenses related to its presence at the ASHP conference, enhanced customer experience initiatives, and HR investments as key drivers. While these costs are framed as strategic and geared toward strengthening long-term growth and customer loyalty, they temporarily weigh on margins and underscore the near-term trade-off between investment and profitability.

Cash Balance Declines After Debt Repayment and Buybacks

Omnicell’s balance sheet showed a notable reduction in cash. Cash and cash equivalents dropped to $197 million at year-end 2025 from $369 million at year-end 2024, a decline of roughly 46.6%. The decrease reflects repayment of $175 million of debt and approximately $78 million of share repurchases, signaling management’s willingness to return capital to shareholders while also delevering. However, free cash flow in Q4 2025 fell to $18 million from $43 million a year earlier, a 58% decline, highlighting the importance of sustaining cash generation as the company continues to invest and face tariff-related headwinds.

Softness in Bookings and Backlog Adds Caution to Growth Outlook

Although bookings came in above guidance midpoints, the year-over-year trend was slightly negative, with 2025 product bookings of $535 million versus $558 million in 2024 and a small 1% decline in backlog. This softness introduces a degree of caution to the growth outlook, particularly as Omnicell seeks to accelerate adoption of new systems and convert its pipeline into firm orders. Investors will be watching whether the strengthened top-of-funnel activity that management described can translate into a reacceleration of bookings in 2026 and beyond.

Tariffs and Supply-Chain Costs Remain a Major Overhang

Tariffs and related supply-chain issues emerged as a structural headwind. In 2025, tariff costs materially contributed to margin compression, and for 2026 Omnicell anticipates about $15 million in tariff-related P&L impact. While the company is undertaking mitigation efforts, these have not fully offset the pressure, and management effectively baked the ongoing cost burden into its guidance. For investors, the key question is how quickly Omnicell can reengineer supply chains, adjust pricing, or shift product mix to blunt this impact without harming competitive positioning.

Retail/EnlivenHealth Pressures Weigh on Parts of the Business

The company also flagged headwinds in the retail market, affecting its EnlivenHealth segment. Management noted ongoing pressures in this area and is monitoring the situation closely, acknowledging that these challenges could constrain parts of the services business. While not the core driver of the overall story, retail segment softness introduces another layer of complexity and highlights Omnicell’s exposure to varying dynamics across healthcare end markets.

Titan XT Ramp Will Take Time to Materialize

Despite the strategic importance of Titan XT, its financial contribution remains in the future. Titan XT launched in December, and Omnicell reported no Titan XT orders in 2025, reflecting the long capital budgeting cycles and multi-quarter to multi-year decision processes typical for large healthcare systems. The company also highlighted the role of leases and financing structures in pacing hardware replacements. This means that while Titan XT could drive growth and mix improvement over time, near-term revenue from the platform is uncertain and will likely ramp gradually rather than in a sharp step-change.

Guidance Signals Modest Growth and Improving Profitability in 2026

For the first quarter of 2026, Omnicell guided total revenue to $300 million to $310 million, with product revenue of $171 million to $176 million and service revenue of $129 million to $134 million. Q1 non-GAAP EBITDA is expected in the range of $27 million to $33 million and non-GAAP EPS of $0.26 to $0.36, with management noting seasonally higher payroll and tax costs. For the full year 2026, the company forecast product bookings of $510 million to $560 million, total revenue of $1.215 billion to $1.255 billion (product $690 million to $710 million; service $525 million to $545 million), and year-end ARR of $680 million to $700 million. Non-GAAP EBITDA is guided to $145 million to $160 million and non-GAAP EPS to $1.65 to $1.85. The outlook incorporates approximately $15 million of tariff costs and about $10 million of ERP implementation expenses, alongside an expected non-GAAP tax rate of around 13%. Management framed the guidance as demonstrating profit growth roughly twice the rate of revenue growth, with more meaningful incremental software revenue from Omnisphere expected to begin in 2027.

Omnicell’s earnings call painted a nuanced picture: solid ARR and service growth, steady overall revenue gains, and a promising innovation pipeline, offset by margin compression, weaker near-term profitability, and a sizable drawdown in cash. The company is clearly in an investment phase, absorbing tariff and ERP costs while funding new platforms and go-to-market efforts. For investors, the key takeaways are that the core business remains fundamentally healthy and increasingly recurring, but the path to higher margins and stronger EPS depends on successful mitigation of external cost pressures and conversion of Titan XT and Omnisphere from promising concepts into material revenue drivers over the next several years.